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1 ASC-US: atypical squamous cells of undetermined significance
2 CIN2+: cervical intraepithelial neoplasia grade 2 or worse
3 CIN3+: cervical intraepithelial neoplasia grade 3 or worse
4 hrHPV+: high-risk HPV-positive
5 LMICs: Low-Middle-Income countries
6 LBC: liquid-based cytology
7
8 Article category: 
9 Cancer Epidemiology
10
11 Novelty and Impact:
12 This is the first triage study among hrHPV+ women with head-to-head comparison of S5-
13 methylation, HPV16/18, and conventional cytology from a LMIC country; we show clear 
14 clinical value for methylation triage. Advances in methylation technologies may allow 
15 implementation of these assays relatively soon in LMIC settings. This availability is likely to 
16 have an important impact on screening and triaging hrHPV+ women algorithms in regions where 
17 greater accuracy of triage and enhanced simplicity of follow-up are urgently needed. 
18
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1 Abstract
2 The S5-methylation test, an alternative to cytology and HPV16/18 genotyping to triage high-risk 
3 HPV-positive (hrHPV+) women, has not been widely validated in Low-Middle-Income countries 
4 (LMICs). We compared S5 to HPV16/18 and cytology to detect cervical intraepithelial neoplasia 
5 grade 2 or worse (CIN2+) and CIN3+ in hrHPV+ women selected from a randomized pragmatic 
6 trial of 2661 Colombian women with an earlier-borderline abnormal cytology. We included all 
7 hrHPV+ CIN2 and CIN3+ cases (n=183) age matched to 183 <CIN2 hrHPV+. Baseline 
8 specimens were HPV-genotyped and tested by S5-methylation, blinded to cytology, histology, 
9 and initial HPV results. We evaluated the test performance of pre-defined S5-classifier (cut-point 
10 0.8) and a post-hoc classifier at a different cut-point (3.1). 
11 S5 sensitivity for CIN2+ was 82% (95%CI 76.4–87.5) and for CIN3+ 77.08% (95%CI 65.19–
12 88.97). S5 sensitivity was higher than HPV16/18 sensitivity (48.1%, 95%CI 40.85–55.33) or 
13 cytology (31.21%, 95%CI 24.50–37.93) but with lower specificity (35%, 95%CI 28.1–42). At 
14 cut-point 3.1, S5 sensitivity for CIN2+ (55.2%, 95%CI 48–62.4) or CIN3+ (64.6%,95%CI 51.0–
15 78.1) was also superior to HPV16/18 (p<0.05) or cytology (p<0.0001). At this cut-point S5 
16 specificity (76%, 95%CI 69.8–82.1 for <CIN2) was higher than HPV16/18 (67.21%, 95%CI 
17 60.41–74.01,p=0.0062) and similar to cytology (75.57% 95%CI 69.34–81.79,p=1).  HPV16/18 
18 plus cytology sensitivity was similar to S5 for CIN3+, however, false-positive rate was higher 
19 (50.27% vs.24.04%).
20 High sensitivity is crucial in LMICs, S5-methylation exceeded HPV16/18 or cytology sensitivity 
21 with comparable specificity for CIN2+ and CIN3+ in hrHPV-positive Colombian women. 
22 Furthermore, S5 triage had comparable sensitivity and significantly fewer false positives than 
23 cytology and HPV16/18 combination.
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1 Introduction
2 Cervical cancer is a leading cause of cancer death for women living in low and middle income 
3 countries (LMICs) where 95% of the approximately 570 000 new cases and 311 000 deaths 
4 (estimated by Globocan for 2018) occur.1 High-risk Human Papillomavirus (hrHPV), a common 
5 sexually transmitted infection worldwide is the cause of almost all cervical cancer. Only a small 
6 proportion of hrHPV infections persist and develop into cervical intraepithelial neoplasia (CIN) 
7 grade 2 or 3 (CIN2 and CIN3) which may, if left untreated, progress to cancer.2 
8 In 2018 the World Health Organization issued a call for action to eliminate cervical cancer by 
9 a comprehensive approach that includes increasing HPV vaccine coverage and screening of 
10 women aged more than 30 years with hrHPV testing followed by treatment of hrHPV-positive 
11 women that in the visual inspection are suspicious of cervical cancer precursor lesions.3 hrHPV 
12 DNA testing has greater sensitivity and negative predictive value for detecting CIN2+ and 
13 CIN3+ (more reproducible and definitive surrogate endpoint of cervical cancer risk) than 
14 cytology,4 which permits longer screening intervals and more cost-effective prevention 
15 programs5.  Because HPV-based screening provides 60–70% greater protection against invasive 
16 cervical carcinomas compared with cytology,6 it is expected that HPV‐based screening would 
17 result in a lower incidence of and mortality from cervical cancer. hrHPV testing is the most  
18 effective approach for reducing cervical cancer mortality especially in LMICs, where 
19 improvement of quality of cytology remains a challenge and the number of life-time screening 
20 visits is low.5 However, hrHPV testing has low specificity, which can increase referrals to 
21 colposcopy, leading to more anxiety and overtreatment of women with non-progressive disease.7 
22 Approaches to stratify (triage) hrHPV-positive women include conventional (Pap smear), 
23 liquid-based cytology (LBC), without or with adjunctive p16/Ki67 double staining (herein 
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1 p16/Ki67 cytology) and HPV16/18 genotyping. Reassurance provided by cytology against false 
2 negatives is low8 and a high proportion of women hrHPV-positive and cytology negative at 
3 screening need further follow-up. p16/Ki67 has both higher sensitivity and specificity than 
4 cytology testing for triage of HPV-positive women and negative results have greater reassurance 
5 against CIN2+ than negative cytological results,9 but as with cytology, good results depend on 
6 expert visual interpretation of well-preserved morphological specimens from LBC, which is an 
7 expensive and subjective expertise not widely available in LMICs. PCR-based HPV16/18 
8 genotyping is a robust, operator independent assay without extra requirements for sample 
9 preservation; however, it reaches a sensitivity of only 50-60%10 and misses all the CIN2+ in 
10 women positive for the other 11 hrHPV types.
11 Deregulated expression of hrHPV E6 and E7 genes can induce uncontrolled cell cycle 
12 progression and favours the development of persistent hrHPV infection and precancer. This 
13 process coincides with a decline in activity of the late capsid genes promoter (L1 and L2), which 
14 shows a higher methylation level in hrHPV-positive women diagnosed with CIN2+.11 In 
15 addition, changes in the levels of methylation of CpG sites in promoters or introns of host-cell 
16 genes such as EPB41L3, JAM3, TERT, CADM1, MAL, mir124, and FAM19A4 are also 
17 associated with higher risk of cervical cancer and its precursor lesions.12 Methylation assays can 
18 be automated, have accurate quantitation, are robust to operator variations and can be performed 
19 in the same specimen as the screening hrHPV tests. These attributes offer opportunities to 
20 develop automated high throughput methylation tests with consequent simplification of currently 
21 available triage algorithms. 
22 The S5 classifier is a test based on DNA methylation of the late regions L1 and L2 of HPV16, 
23 HPV18, HPV31 and HPV33 combined with the promoter region of human tumour suppressor 
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1 gene EPB41L3 that identifies women with CIN2+.13 At sensitivities of 90% (95% CI 87–92) or 
2 74% (95% CI 59–85), S5 showed a specificity of 49% (95% CI 46–52) or 65% (95% CI 60–70) 
3 for the detection of CIN2+ in women who attended colposcopy13 or screening14 health services in 
4 London, UK respectively. The S5 classifier showed similar performance in samples selected 
5 from women attending primary cervical screening in Canada.15 
6 Although earlier studies in developed countries have shown that the performance of the S5 
7 classifier to detect CIN2+ is superior to that of HPV16/18 genotyping and similar to complex 
8 triage strategies such as a combination of repeated LBC and HPV genotyping,15 there are few 
9 studies validating S5 in LMIC settings16. Thus, we compared the performance of the S5 DNA 
10 methylation classifier with repeated conventional cytology at 6 and 12 months and baseline 
11 HPV16/18 genotyping for detection of 2 year-endpoint CIN2+ and CIN3+ in hrHPV-positive 
12 women selected from a pragmatic trial (ASC-US-COL trial) that recruited women from routine 
13 opportunistic screening services of Colombia, a middle-income country.
14
15 Material and Methods
16 ASC-US-COL study design.
17 ASC-US-COL is a three-arm, non-blinded, parallel group, pragmatic trial.17 Women aged 20-69 
18 years (n=2661) with a first time atypical squamous cells of undetermined significance (ASC-US) 
19 cytology in the last 2 years were flagged in routine screening services and randomly allocated to 
20 receive immediate colposcopy (IC arm; n=882), repeat cytology at 6 and 12 months (RC arm; 
21 n=890) or an HPV test within 2 months of recruitment (HPV arm; n=889). Colposcopy and 
22 biopsies according to clinician judgment were recommended for all women in the IC arm, for 
23 women with a repeat ASC-US or worse (ASC-US-positive) in the RC arm and for hrHPV+ 
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1 women in the HPV arm. Hybrid Capture 2 HPV DNA test (HC2©, QIAGEN, Germantown 
2 USA) with a relative light unit/cut-off (RLU/Co) ratio of ≥1 for considering an HPV result 
3 positive, was conducted at the laboratory of Infection and Cancer, University of Antioquia, 
4 Colombia. All women received invitation for and 80% (n= 2132 women) attended the exit visit 
5 after 24 months of follow-up which included hrHPV and cytology tests. All women positive for 
6 either test were referred to a certified, well-trained colposcopist using a standardized and 
7 controlled protocol of biopsy sampling. At the end of the study, two blinded accredited experts 
8 confirmed histopathological diagnoses and baseline samples of women from IC and RC arms 
9 were tested for hrHPV by HC2© (QIAGEN).
10
11 Selection of methylation sub-study participants.
12 Cases were women identified after the end of the ASC-US-COL trial as women who had hrHPV-
13 positive test results at baseline (recruitment visit) and with a colposcopy-directed biopsy 
14 diagnosis of CIN2, CIN3, or carcinoma in situ, adenocarcinoma (ADC) or squamous cell 
15 carcinoma (SCC) at any time during the 2-year follow-up. Controls were randomly selected 
16 regardless of arm allocation from women who were hrHPV-positive at baseline, had a biopsy 
17 with a diagnosis of less than CIN2 (<CIN2) during the follow-up confirming that they were at 
18 low risk of cervical cancer and with enough remainder of archived baseline samples in specimen 
19 transport medium (STM; QIAGEN) for further testing. Controls were individually matched to 
20 cases by age and time to diagnosis (±12 months). As shown in the flowchart (Figure 1), 185 
21 cases (137 CIN2, 44 CIN3 and 4 SCC) and 185 matched controls (143 biopsies Negative and 42 
22 CIN1) were identified for the study. The CLART® HPV4 (Clinical Array Technology, 
23 Genomica®, Madrid, Spain) test was used for HPV genotyping at the Queen’s Medical Research 
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1 Institute of The University of Edinburgh (Edinburgh, UK). Two CIN2 cases that were inadequate 
2 in the HPV genotyping test and their corresponding controls (biopsy negative) were excluded. 
3 There were no equivocal results in S5 methylation assays, therefore 183 pairs were evaluated by 
4 all tests. 
5
6 Methylation study specimen characteristics
7 Exfoliated cervical cells in the ASC-US-COL trial were collected in STM and immediately 
8 stored at -30°C. Samples were thawed and denatured at the time of HC2 testing. DNA was 
9 extracted from 200µL of the residual content. Briefly, STM specimens were digested for 2 h at 
10 55°C in the presence of 200 µg/ml of proteinase K and 1% Laureth-12. Samples were 
11 centrifuged for 30 seconds at maximum speed in an Eppendorf microcentrifuge and then heated 
12 to 95°C for 10 min. After precipitation with 0.5M ammonium-acetate and 70% ethanol, DNA 
13 was washed, dried and resuspended in 100µL of TE buffer (10mM TRIS/0.1mM EDTA).18 DNA 
14 quality and quantity were assessed using Nanodrop and PCR amplification for the MID856 
15 variant as internal control.19 Isolated DNA was stored at –30°C and shipped frozen on dry ice to 
16 Queen Mary University of London for S5 methylation testing. 
17
18 HPV genotyping 
19 HPV genotyping was independently and blindly conducted on 5µL of a 1:10 dilution of each 
20 specimen using the CLART® HPV4 test (Genomica®, Madrid, Spain). This test uses 
21 biotinylated MY09/11 consensus primers and detects 13 hrHPV types, (16, 18, 31, 33, 35, 39, 
22 45, 51, 52, 56, 58, 59, 68), one presumptive low risk type HPV66,  and 21 low-risk types (26, 53, 
23 70, 73, 82, 85, 6, 11, 40, 42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 84, 89). High proficiency of the 
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1 detection of the PCR products by the low-density microarray platform CLART has been 
2 reported.20
3
4 S5 DNA methylation classifier testing.
5 Methylation assays were based on end-point PCR and quantitative pyrosequencing of amplicons 
6 using primers for 6 target regions covering in total 22 CpG positions of human gene 
7 EPB41L3 and the late (L1 and L2) regions of HPV16, HPV18 and HPV31 and HPV33, as 
8 detailed previously.14 Briefly, 100 ng of DNA was used for bisulphite conversion where 
9 unmethylated cytosines were converted to uracil with the EZ-DNA methylation kit (Zymo 
10 research, Irvine, CA). Converted DNA (2 µL/sample) was added to PCR master mix and 
11 amplified by methylation independent PCR primers. Quality of the amplified DNA was 
12 confirmed on a QIAxel capillary electrophoresis instrument (Qiagen). Twenty-five μL of PCR 
13 product was used for pyrosequencing (PyromarkQ96 ID Platform, Qiagen, Germany). The S5 
14 score was defined as 30.9(EPB41L3) + 13.7(HPV16L1) + 4.3(HPV16L2) + 8.4(HPV18L2) + 




19 The analysis was based on a pre-specified analytical plan. The primary hypothesis was that using 
20 the hrHPV-positive baseline samples, S5 at the standard pre-defined cut-point 0.813 can 
21 distinguish between <CIN2 and CIN2+ (includes CIN2, CIN3 and cancer) and also have a very 
22 high sensitivity for CIN3+. We also compared the sensitivity of S5 with the other tests at a 
23 specificity of 75% that corresponds to using a positivity threshold of 3.1. We used this threshold 
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1 for S5 because it gave the same specificity as cytology, the currently recommended triage test for 
2 hrHPV+ women in the Colombian screening guidelines. The specificity of S5 for CIN3+ was 
3 calculated by omitting CIN2 cases because this is an intermediate category and it is not correct to 
4 combine it with the normal and CIN1 diagnoses, which have minimal risks for cervical cancer. 
5 The Cuzick test for trend was used to investigate continuous changes in methylation with 
6 increasing lesion severity. The sensitivity and specificity of cytology was determined using the 
7 highest-grade cytology from the 6 and 12-month samples after the initial entry ASC-US 
8 cytology, at an ASC-US-positive threshold. The performance of continuous risk scores was 
9 measured by area under the curve (AUC) with a Wilcoxon test and DeLong confidence 
10 intervals.21 Differences in sensitivities and specificities of S5 with the other tests were examined 
11 by McNemar’s test with continuity correction. Statistical analysis was conducted in R version 
12 3.5.2.22 A p value of <0.05 was considered significant. 
13
14 Results
15 Characteristics of study population
16 Figure 1 shows that 5 of the 2661 women included in the ASC-US-COL trial did not have an 
17 HC2 HPV DNA test result and that 364 (41%) women in the IC arm, 396 (44.5%) in the RC arm 
18 and 362 (40.7%) in the HPV arm were hrHPV-positive. Among the 1122 hrHPV+ women, 734 
19 (65.4%) had an adequate histological diagnosis, 549 of which had a diagnosis of <CIN2 (404 
20 Negative and 145 CIN1) and 185 of CIN2+ (137 CIN2, 44 CIN3, and 4 cancers). After exclusion 
21 of 4 samples (2 cases inadequate in the HPV genotyping test and corresponding controls), 34.2% 
22 (138/404), 31.0% (45/145), 98.5% (135/137) and 100 % (48/48) of women with Negative, CIN1, 
23 CIN2 or CIN3/SCC histopathological diagnosis were included in this analysis. Table 1 describes 
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1 the characteristics of the included 183 CIN2+ cases and 183 <CIN2 controls. Cases and controls 
2 had similar age, time to diagnosis (±12 months), age distribution at first sexual intercourse, 
3 number of sexual partners, distribution of cytological interpretations and arm allocation. HPV16 
4 was confirmed in 131 (35.8%), HPV18 in 24 (6.6%), HPV31 in 47 (12.8%) and HPV33 in 23 
5 (6.3%) of all samples. 82 (44.8%) of CIN2+ were positive for HPV16, 10 (5.5%) for HPV18, 24 
6 (13.1%) for HPV31 and 17 (9.3%) for HPV33. 
7
8 EPB4IL3, HPV16L1, and S5 methylation patterns were related to the severity of CIN
9 Median S5 methylation (Figure 2) increased proportionally (Cuzick trend test χ2=45.1, 
10 p<0.0001) with histopathological diagnosis: 1.0 in histology Negative (n=138), 1.4 in CIN1 
11 (n=45), 3.4 in CIN2 (n=135), 7.1 in CIN3 (n=44) and 10.8 in cancer (n=4). Figure 3 shows 
12 similar patterns of methylation levels increasing by lesion severity for EPB4IL3 (Figure 3a, 





18 Performance of the S5 classifier to detect CIN2+ or CIN3+ 
19 The ROC curve showed that S5 had an AUC of 0.70 (95% CI 0.64–0.75, p<0.0001 ) for CIN2+ 
20 and of 0.72 (95% CI 0.65–0.80, p<0.0001) for CIN3+ (Figure 4).  Cross tabulation of the number 
21 of cases or controls with negative or positive test results and the comparison of sensitivities and 
22 specificities of the tests to detect CIN2+ or CIN3+ are shown in Table 2 and Table 3 
23 respectively. For CIN2+, the sensitivity of HPV16/18 was 48.1% (95% CI 40.8–55.3) and of 
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1 cytology was 31.2% (95% CI 24.5–37.9). S5 at the predefined cut-point of 0.8 had a higher 
2 sensitivity (82.0%, 95% CI 76.4–87.5) but significantly lower specificity (35.0%, 95% CI 28.1–
3 41.9) than HPV16/18 (67.2%, 95% CI 60.4–74.0,  p<0.0001) or cytology testing (75.6%, 95% CI 
4 69.3–81.8, p<0.0001). At the cut-point of 3.1, (corresponds to setting the specificity of S5 for 
5 <CIN2 at 76% which is equal to cytology specficity)  the S5 specifity was significantly higher 
6 than HPV16/18-genotyping  (p=0.0062), while the sensitivity of S5 was 55.2% (95% CI 48.0–
7 62.4), which remained significantly higher than sensitivity of HPV16/18 genotyping (p=0.0164) 
8 and of cytology (p<0.0001). 
9 Likewise to the observations with CIN2+, the sensitivity for CIN3+ of S5 at the cut-point 0.8 
10 (77.1%, 95% CI 65.2–89.0,) was higher than the sensitivity of HPV16/18 genotyping (50%, 95% 
11 CI 35.9–64.1, p=0.0008) or cytology (37.0%, 95% CI 23.3–50.6, p=0.0003). At the cut-point of 
12 3.1, the S5 sensitivity for CIN3+ was 64.6% (95% CI 51.0–78.1) which remained significantly 
13 higher than the sensitivity of HPV16/18 (p=0.0233) and of cytology (p=0.0088). The 
14 combination of cytology with HPV16/18 increased sensitivity to 63.4% (95% CI 56.4–70.4) for 
15 CIN2+ and to 64.6% (95% CI 51.0–78.1) for CIN3+ and exceeded the sensitivity of S5 for 
16 CIN2+ but not for CIN3+. However, the specificity of the combination of these tests for <CIN2 
17 (49.73% 95% CI 42.48–56.97) was lower than the corresponding specificity of S5 at the 3.1 cut-
18 point (p<0.0001).
19 Combining sensitivity and specificity, the accuracy of S5 at a cut-point of 3.1 for detection of 
20 both CIN2+ (Table S1, 0.66, 95% CI 0.60–0.70, p=0.0001) and CIN3+ (Table S2, 0.75, 95%CI 
21 0.67–0.79, p=0.0033) was significantly higher than the accuracy of the HPV16/18 test (0.58, 
22 95% CI 0.52–0.63 for CIN2+; 0.63, 95% CI 0.57–0.70 for CIN3+) or when this test was 
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1 combined with cytology (0.57, 95%CI 0.51–0.62, p=0.0014 for CIN2+ and 0.53, 95% CI 0.46–
2 0.49,  p<0.0001 for CIN3+).  
3
4 Discussion
5 Because HPV testing has higher sensitivity and negative predictive value than cytology for 
6 detection of cervical high-grade lesions, it has the potential to increase the detection of disease 
7 and lengthen the screening intervals. The World Health Organization23 recommends visual 
8 assessment for treatment (VAT) after positive HPV DNA testing for populations living in remote 
9 areas where there are few opportunities to screen women at proper intervals and for follow-up 
10 after screening. Most HPV infections are transient so immediate ablative treatments can lead to 
11 unnecessary gynaecological harms for women with low risk of disease. For this reason, primary 
12 screening with hrHPV testing requires other triage tests to identify women at higher-risk of high-
13 grade disease among those who are hrHPV-positive. Re-calling women for a second test after 
14 screening is challenging or impossible in LMICs, therefore, risk stratification should ideally 
15 occur at the screening visit in these settings. Hence, these settings have unique needs for triage 
16 strategies. Currently, LBC or conventional cytology, p16/Ki67 cytology and HPV16/18 are 
17 recommended tests for triage hrHPV-positive women, but HPV self-sampling,24 a strategy that 
18 increases screening coverage of women living in rural and dispersed environments, precludes the 
19 use of cell-based tests. HPV16 the genotype associated with the greatest elevated risk of cervical 
20 high-grade lesions, offers an alternative for immediate identification of women who should be 
21 referred for diagnosis and treatment. HPV18 has been included with HPV16 as a combination 
22 triage because it is a highly prevalent virus in squamous cancers and adenocarcinomas, although 
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1 not in CIN3. However, HPV16/18 reaches a sensitivity of only 50-60% and women positive for 
2 the other 11 hrHPV types require further management with cytology. 
3 Changes in the levels of methylation of HPV DNA and CpG sites in promoters or introns of 
4 host-cell genes are associated with higher risk of cervical cancer and precursor lesions. Recent 
5 meta-analysis and systematic reviews have shown that AUC values for methylation of L1 gene in 
6 all HPV genotypes for prediction of CIN2+ or CIN3+ range from 0.65 to 0.9525 and that markers 
7 of host DNA methylation, with specificity set at 70%, have a sensitivity for CIN2+ and CIN3+ 
8 of 68.6% (95% CI 62.9–73.8) and 71.1% (95% CI 65.7–76.0), and positive predictive values of  
9 53.4% (95% CI 44.4–62.1) and 35.0% (95% CI 28.9–41.6) respectively26. Methylation also 
10 exhibited higher specificity than cytology (at an ASC-US threshold) and higher sensitivity than 
11 HPV16/18 to detect CIN2+ and CIN3+ among hrHPV-positive. Because of the heterogeneity of 
12 assays and targets to estimate the level of methylation, and because some studies did not have 
13 histopathology verification, there is need of further confirmation of these conclusions. In contrast 
14 to cell-based methods, DNA methylation can be reflexed using the same cervical exfoliates used 
15 for HPV testing and the molecular methods offer the possibility for self-sampling. These 
16 characteristics make a methylation-based test a very good candidate for immediate triage and 
17 treatment where necessary when self-sampling is used as the primary test. However there are 
18 very few studies validating methylation markers in women from LMICs25, 26, which are the 
19 countries with the highest cervical cancer incidence and mortality rates.
20 Here we have evaluated the S5 classifier, a multigene methylation test, which has very well 
21 validated procedures and parameters for estimating the methylation levels and that has shown 
22 good performance in UK14, Canada15 and Mexico.16 Our study included 366 hrHPV+ baseline 
23 samples from women who had two years of active follow-up culminating in colposcopically-
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1 directed biopsy diagnoses if positive for either hrHPV or cytology tests. These women had most 
2 of the high-grade cervical precancerous endpoints identified from among the 2661 participants of 
3 ASC-US-COL study.17 To address potential bias in methylation levels by age at diagnosis or 
4 time of follow-up, our controls were age- and time to diagnosis matched and randomly chosen 
5 among all baseline hrHPV+ women. The genotyping and methylation assays, as well as the 
6 verification of the histological diagnoses, were conducted independently and blindly after the 
7 end of the study. To date there are very few reports comparing the performance of cytology and 
8 HPV16/18 genotyping with DNA methylation assays to detect CIN2+ and CIN3+ in hrHPV+ 
9 women.15, 27-30 The study allowed us to objectively compare the performance of S5 for CIN2+ 
10 and CIN3+ detection versus twice repeated cytology testing and HPV16/18 in hrHPV+ women 
11 in an LMIC setting. 
12 The AUCs of the continuous S5 classifier for CIN2+ and CIN3+  were not different (0.70 vs. 
13 0.72; p=0.6218, DeLong’s test) and were similar to those obtained in a population-based HPV 
14 cervical screening clinical trial in Canada,15 but lower than the AUC (0.82) seen in women 
15 attending colposcopy in UK.13 At a specificity set at 76.0% that corresponds to using S5 at a cut-
16 point of 3.1, the sensitivity of S5 for CIN2+ and for CIN3+ were 55.2% and 64.6% respectively, 
17 which were significantly higher than the sensitivities of HPV16/18 (p=0.0164 and p=0.0233, 
18 respectively) or cytology (p<0.0001 and p=0.0088, respectively). Performance of S5 was similar 
19 to the comparator triage tests and their combination regarding the specificity. Considering that 
20 we are comparing different triage tests among women with above the average risk for CIN2+ 
21 (previous ASC-US cytology and hrHPV+), S5 offers a good triage alternative since this test 
22 decreased the false positive rate by near 9% (Table 3)  and exhibited higher sensitivity than 
23 HPV16/18, cytology or combination of these two tests for both CIN2+ and CIN3+ endpoints. 
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1 This characteristic of S5 is especially valuable for remote areas of LMICs, where higher 
2 sensitivity is crucial to identify at-risk women in fewer screening visits and decreasing the use of 
3 resources to follow-up women with low risk of disease. 
4 In our study, cytology had a specificity of 75%, but was the test with by far the highest false 
5 negative rate. We recognize that the sensitivity of our cytology was much lower than the 
6 performance of this test seen in specialist centres, but several studies have demonstrated that the 
7 sensitivity in LMICs including some Latin American countries may be as low as 30%.31-34 It is 
8 worth noting that despite many  efforts to improve cytology quality and sensitivity, difficulties in 
9 quality control and delays in diagnosis still prevail.5  
10 It is recognized that borderline and mild cytology have low reproducibility. Furthermore, 
11 since we matched controls to cases by age and hrHPV status, the distribution of cytology grades 
12 of controls may be biased. Thus, our results must be interpreted with the knowledge that ASC-
13 US diagnoses and cytology grades distribution may not be comparable to other clinical settings. 
14 The appropriate sensitivity/specificity combination (and the corresponding decision threshold) of 
15 the methylation tests for the application of triaging hrHPV+ women has not been defined. In one 
16 meta-analysis the pooled sensitivity and specificity for CIN2+ was estimated irrespective of 
17 threshold used to define methylation positivity.25 In the other, the threshold  corresponded to a 
18 specificity of 70%.26 We used the pre-specified 0.8 cut-point that corresponded to a sensitivity of 
19 90% (95%CI 87–92) and a specificity of 49% (95%CI 46–52) in a previous study with S5,13 and 
20 conducted a post-hoc analysis setting the specificity at 76% that corresponded at 3.1 cut-point. 
21 Future work is planned to assess the performance of S5 as a triage for HPV-positive tests to 
22 determine appropriate cut-offs within a screening population. Also, further work is needed to 
23 determine the performance of the S5 methylation assay in vaccinated populations.
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1 Despite the differences in study designs and the proportion of CIN2+ and CIN3+ cases 
2 included, the consistency of our results are remarkably similar to what has been observed 
3 previously13.  The S5 methylation test accurately identified women with higher risk of cervical 
4 high-grade disease and cancer among those who were hrHPV+. Even further, our study 
5 demonstrated that S5 outperforms both cytology and HPV16/18 CIN2+ and CIN3+ detection in 
6 hrHPV+ women.14-16  Currently S5 DNA methylation test is labour intensive and costly.  The 
7 recent developments of affordable and scalable next generation sequencing assays35 strengthens 
8 our proposal that the S5 DNA methylation classifier test may be an acceptable strategy for the 
9 triage of hrHPV+ in LMICs. Strategies combining screening and immediate clinical management 
10 are urgently needed for low-resource settings where infrastructure for follow-up after screening 
11 is limited. Our results warrant further clinical validation of S5 in large prospective population-
12 based screening trials. 
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7 Figure 1. Flowchart
8
9 Figure 2. Boxplot distribution of S5 risk score  according to the lesion group. The median and 
10 interquartile range are depicted by boxes. Cuzick trend test  χ2= 45.1 (p<0.001).
11
12 Figure 3. Boxplot distribution of (a) EPB41L3 methylation (Cuzick trend test  χ2= 23.47, 
13 p<0.001) and (b) HPV16-L1 methylation (Cuzick trend test  χ2= 25.40, p<0.001) by histology.
14
15 Figure 4. ROC plot of S5 classifier for (a) CIN2+ and (b) CIN3+. As comparison sensitivity and 
16 specificity cutpoints of S5 classifier at cut-offs of ≥0.8, ≥1.4 or ≥3.1,  Cytology (Positive = worst 
17 cytology repeated at 6 or 12 months after first ASC-US cytology, at a threshold, ASC-US or 
18 above), HPV16/18 and cytology plus HPV16/18 are depicted. The CIN2 cases were excluded in 
19 the analysis for the CIN3 endpoint, as CIN2 would be treated as false positive when included 
20 with <CIN2  
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Table 1.  Description of study population
Characteristic  Control (n=183)  Case (n=183)  p value*
Number  n (%) n (%) -
Age (years) 0.2164
20–29 91 (49.73) 80 (43.72)
30–39 50 (27.32) 66 (36.07)
40–49 34 (18.58) 26 (14.21)
>=50 8 (4.37) 11 (6.01)
Time to histological diagnosis (months) 0.0604
1–12 109 (59.56) 98 (53.55)
13–>18 74 (40.43) 85 (46.44)
Age of first sexual intercourse (years) 0.0595
≤15 42 (22.95) 58 (31.69)
16–19 102 (55.74) 100 (54.64)
≥20 39 (21.31) 25 (13.66)
Number of sexual partners 0.659
1–3 94 (51.37) 87 (47.54)
4–5 40 (21.86) 47 (25.68)
≥6 49 (26.78) 49 (26.78)
hrHPV types frequency 
HPV 16 49 (26.78) 82 (44.81) 0.0005
HPV 18 14 (7.65) 10 (5.46) 0.5264
HPV 31 23 (12.57) 24 (13.11) 1
HPV 33 6 (3.28) 17 (9.29) 0.0312
Other hrHPV types¥ 142 (77.6) 124 (67.76) 0.0461
Cytology 0.1678
NEG 133 (72.68) 119 (65.03)
LSIL 23 (12.57) 28 (15.3)
HSIL 0 (0) 3 (1.64)
ASC-US 20 (10.93) 20 (10.93)
ASC-H-AGC/ASC-H 0 (0) 3 (1.64)
Missing 7 (3.83) 10 (5.46)
Arm 0.6674
RC 58 (31.69) 65 (35.71)
IC 64 (34.97) 57 (31.32)
HPV 61 (33.33) 60 (32.97)
*Person's chi-squared test. The percentage is shown in column. NEG= negative, 
LSIL= Low Grade Squamous Intraepithelial Lesion, HSIL= High Grade squamous 
intraepithelial lesion, ASC-US= Atypical Squamous Cells of Undetermined 
Significance, ASC-H-AGC= Atypical squamous cells, cannot exclude HSIL or 
Atypical Glandular Cells, ASC-H = Atypical squamous cells, cannot exclude 
HSIL. RC= Repeat cytology, IC= Immediate colposcopy, HPV = Human 
Papillomavirus test. ¥Other hrHPV types = HPV 35, 39, 45, 51, 52, 56, 58, 59. 
 Worst cytology result after ASC-US index cytology. 
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Table 2. Number and percentages of<CIN2 controls and CIN2+ and CIN3+ cases with negative or positive tests results
 <CIN2 (n=183) CIN2+ (n=183) CIN3+ (n=48)
TN n (%) FP n (%) TP n (%) FN n (%) TP n (%) FN n (%)
S5 different cut-off
S5 ≥0.8* 64 (34.97) 119 (65.03) 150 (81.97) 33 (18.03) 37 (77.08) 11 (22.92)
S5 ≥3.1¥ 139 (75.96) 44 (24.04) 101 (55.19) 82 (44.81) 31 (64.58) 17 (35.42)
HPV16/18 123 (67.21) 60 (32.79) 88 (48.09) 95 (51.91) 24 (50) 24 (50)
Cytology 133 (75.57) 43 (24.43) 54 (31.21) 119 (68.79) 17 (36.96) 29 (63.04)
Cytology plus HPV16/18£ 91 (49.73) 92 (50.27) 116 (63.39) 67 (36.61) 31 (64.58) 17 (35.42)
Positive tests cut-offs: *S5 score ≥0.8 or ¥S5 score ≥3.1, First ≥ASC-US result of cytology repeated at 6 or 12 
months after first time ASC-US cytology. 2 CIN3+ and 8 CIN2 cases and 7 <CIN2 controls have missed results 
for cytology. £Positive for any of the two tests. TP=true positive. FN=false negative. TN=true negative. FP=false 
positive. 
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Table 3. Diagnostic performance of three triage tests and selected combinations for detection of CIN2+ and CIN3+
 <CIN2 (n=183) CIN2+ (n=183) CIN3+ (n=48)
Specificity, % (95%CI)
p valueα 
S5 ≥0.8 vs. 
other tests
p valueα 




S5 ≥0.8 vs. 
other tests





S5 ≥0.8 vs. 
other tests
p valueα 
S5 ≥3.1 vs. 
other tests
S5 different cut-off
S5 ≥0.8* 34.97 (28.06–41.88) NA NA 81.97 (76.40–87.54) NA NA 77.08 (65.19–88.97) NA NA
S5 ≥3.1¥ 75.96 (69.76–82.15) <0.0001 NA 55.19 (47.99–62.40) <0.0001 NA 64.58 (51.05–78.11) 0.0412 NA
HPV16/18 67.21 (60.41–74.01) <0.0001 0.0062 48.09 (40.85–55.33) <0.0001 0.0164 50 (35.86–64.14) 0.0008 0.0233
Cytology, e 75.57 (69.34–81.79) <0.0001 1 31.21 (24.50–37.93) <0.0001 <0.0001 36.96 (23.30–50.61) 0.0003 0.0088
Cytology plus HPV16/18£ 49.73 (42.48–56.97) 0.0015 <0.0001 63.39 (56.41–70.37) <0.0001 0.0213 64.58 (51.05–78.11) 0.1489 1
Positive tests cut-offs: *S5 score ≥0.8 or ¥S5 score ≥3.1, First ≥ASC-US result of cytology repeated at 6 or 12 months after first time ASC-US cytology. 2 CIN3+ and 8 CIN2 
cases and 7 <CIN2 controls have missed results for cytology. Only paired results were included in the McNemar test. £Positive for any of the two tests. αp value of McNemar 
test for comparison of S5 at cut-off 0.8 or 3.1 with each other tests. NA: Not Applicable: same test comparison or compared in previous row.
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7866 women with ASC-US 
4509 assessed for eligibility
2661 randomized
3357 not eligible for the study 
           856 not aged between 19 to 69 years
           513 residence place outside the study area
         1988 ASC-US cytology result older than 3 months
1848 excluded 
        1134 did not meet full inclusion criteria
          702 declined to participate 
            12 deferred 







171 no biopsy 
2 unsatisfactory result
5 indeterminate
889 hr-HPV triage (HPV)
362 HPV positive
282 colposcopy/biopsy









1 ungraded lesion 




131 NEG 48 CIN1 45 CIN2 2 SCC/ADC14 CIN3 115 NEG 36 CIN1 48 CIN2 2 SCC/ADC17 CIN3
138 NEG 45 CIN1 135 CIN2 4 SCC/ADC44 CIN3
158 NEG 61 CIN1 44 CIN2 0 SCC/ADC13 CIN3
Selection of 185 cases CIN2+ and 185 controls <CIN2 , matched by age and time of follow-up at diagnosis 
370 genotyping test and methylation assays 
4 excluded
       1 genotyping PCR inhibited and 1 matched control 
       1 insufficient material and 1 matched control
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